20662-52-6

Basic information

• Product Name: 4,4-Bis(4-fluorophenyl)butyric acid
• Synonyms: 4,4-bis(4-fluorophenyl)butyric acid;4,4-Bis(4-fluorophenyl)butanoic acid;4,4-Bis(p-fluorophenyl)butyric acid;4,4-BIS(4''-FLUOROPHENYL)BUTANOIC ACIDPENFLURIDOL;4,4-Di(p-fluorophenyl)butyric acid;Einecs 243-949-8
• CAS NO: 20662-52-6
• Molecular Formula: C₁₆H₁₄F₂O₂
• Molecular Weight: 276.28
• EINECS: 243-949-8
• Product Categories: API intermediates
• Mol File: 20662-52-6.mol
• Article Data: 5

Chemical Properties

• Boiling Point: 379.572 °C at 760 mmHg
• Flash Point: 183.359 °C
• Appearance: /
• Density: 1.244 g/cm³
• Storage Temp.: Sealed in dry,Room Temperature
• PKA: 4.66±0.10(Predicted)
• CAS DataBase Reference: 4,4-Bis(4-fluorophenyl)butyric acid(CAS DataBase Reference)
• NIST Chemistry Reference: 4,4-Bis(4-fluorophenyl)butyric acid(20662-52-6)
• EPA Substance Registry System: 4,4-Bis(4-fluorophenyl)butyric acid(20662-52-6)

Safety Data

• Hazardous Substances Data: 20662-52-6(Hazardous Substances Data)

Usage

General Description

4,4-Bis(4-fluorophenyl)butyric acid, also known as FFB, is a chemical compound with the molecular formula C18H16F2O2. It is a synthetic compound belonging to the class of phenylalkanoic acids. FFB is commonly used in the pharmaceutical industry as a precursor for the synthesis of various drugs, particularly in the development of nonsteroidal anti-inflammatory drugs (NSAIDs). It is also being studied for its potential use in the treatment of neurological disorders, such as Alzheimer's disease and schizophrenia, due to its ability to modulate the gamma-aminobutyric acid (GABA) neurotransmitter system. FFB has also shown promise in research as a potential therapeutic agent for the treatment of cancer and inflammatory conditions.

InChI:InChI=1/C16H14F2O2/c17-13-5-1-11(2-6-13)15(9-10-16(19)20)12-3-7-14(18)8-4-12/h1-8,15H,9-10H2,(H,19,20)

Upstream product

• 337506-83-9 1,1-bis(4-fluorophenyl)butane-1,4-diol 
• 352-13-6 4-flourophenylmagnesium bromide 
• 462-06-6 fluorobenzene 
• 366-77-8 4-(4-fluorophenyl)-4-oxopropionic acid 
• 50337-85-4 4,4-bis(4-fluorophenyl)butan-1-ol 
• 51787-96-3 5-(4-fluorophenyl)dihydrofuran-2(3H)-one 

Downstream Products

• 1266656-43-2 8-(4,4-bis(4-fluorophenyl)butanoyl)-1-phenyl-1,3,8-triazaspiro[4.5]decan-4-one 
• 26864-56-2 penfluridol 
• 50830-38-1 1-[4,4-bis(4-fluorophenyl)butyryl]-4-(3-trifluoromethyl-4-chlorophenyl)-4-piperidinol 
• 57668-61-8 4,4'-(4-bromobutane-1,1-diyl)bis(fluorobenzene) 
• 68351-25-7 6-Fluor-1-(4-fluor-phenyl)-1,2-dihydro-naphthalin 
• 808749-38-4 (1-{1-[4,4-bis(4-fluorophenyl)butyryl]piperidin-4-ylcarbamoyl}-3-methylbutyl)carbamic acid tert-butyl ester 
• 808749-39-5 (1-{1-[4,4-bis(4-fluorophenyl)butyryl]piperidin-4-ylcarbamoyl}-3-methylbutyl)methylcarbamic acid tert-butyl ester 
• 808749-29-3 4,4-bis(4-fluorophenyl)-N-(piperidin-4-yl)butyramide 
• 808749-34-0 1-(4-aminopiperidin-1-yl)-4,4-bis(4-fluorophenyl)butan-1-one 
• 1002750-52-8 1-(4,4-dihydroxypiperidin-1-yl)-4,4-bis-(4-fluorophenyl)butan-1-one 
• 808749-33-9 (1-[4,4-bis(4-fluorophenyl)butyryl]piperidin-4-yl)carbamic acid tert-butyl ester 
• 808749-28-2 N-(1-benzylpiperidin-4-yl)-4,4-bis(4-fluorophenyl)butyramide 
• 68351-21-3 7-Fluoro-4-(4-fluorophenyl)-1,2,3,4-tetrahydronaphthalene-1-one 
• 50337-85-4 4,4-bis(4-fluorophenyl)butan-1-ol 

Relevant articles and documents

Fluspirilene Analogs Activate the 20S Proteasome and Overcome Proteasome Impairment by Intrinsically Disordered Protein Oligomers

Oligomerization of aggregation-prone intrinsically disordered proteins (IDPs), such as α-synuclein, amyloid β, and tau, has been shown to be associated with the pathogenesis of several neurodegenerative diseases, including Parkinson's and Alzheimer's disease. The proteasome is charged with regulating cellular levels of IDPs, but this degradation pathway can become dysregulated leading to their accumulation and subsequent aggregation. Although the pathogenesis of these neurodegenerative diseases is still under intense investigation, it has been shown that the oligomeric forms of IDPs, including α-synuclein and amyloid β, can impair proteasome function. This leads to additional accumulation of the IDPs, further promoting disease progression. Herein, we report the use of small molecule activators of the 20S subcomplex of the proteasome to restore impaired 20S proteasome activity and prevent IDP accumulation and oligomerization. We found that fluspirilene and its new synthetic analog (16) show strong 20S proteasome enhancement (doubling 20S proteolytic activity at μ2 μM, with maximum fold enhancement of μ1000%), overcome impaired proteasome function, and prevent the accumulation of pathogenic IDPs. These findings provide support for the use of 20S enhancers as a possible therapeutic strategy to combat neurodegenerative diseases.

Synthesis and SAR study of diphenylbutylpiperidines as cell autophagy inducers

A novel series of diphenylbutylpiperidines as autophagy inducers was described and extensive SAR studies resulted in derivatives (15d-e, 15i-j) with 10-fold greater activity than the lead compounds 1 and 2. Meanwhile, a new synthetic route to diphenylbutyl bromide (6) from bromobenzene and γ-butyrolactone was also reported here.

Neurotropic and psychotropic agents. LXVII. 1 [4,4 bis(4 fluorophenyl)butyl] 4 hydroxy 4 (3 trifluoromethyl 4 chlorophenyl)piperidine and related compounds: new synthetic approaches

-